久しぶりの花火、江東花火大会でした！

Alnylam Assist provides patients in the U.S. prescribed our #hATTR #amyloidosis therapy with a broad range of services from answering questions about insurance coverage to financial support for eligible patients.

約1年ぶりのFenway Parkでした！

また、今日からテッペン目指して頑張るかな！

This morning, our partner @MDCONews shared topline results from the ORION-11 Phase 3 study of inclisiran, our investigational #RNAi therapeutic for the treatment of hypercholesterolemia. #PCKS9 #siRNA bwnews.pr/2Nxcakn

Sometimes, a picture can paint a thousand words. Submit your original artwork expressing what it’s like to live with #hATTR #amyloidosis and select pieces will be featured in a calendar shared at the Amyloidosis Support Biennial ATTR Meeting in Chicago in October!

Cardiometabolic disease remains the #1 killer in U.S. There is a huge need for new Rx innovation! Investigational #RNAi therapeutics are under evaluation for some conditions: inclisiran for LDL, ALN-AGT for BP, ALN-HSD for NASH. amp.cnn.com/cnn/2019/08/27…

The Phase 3 results for our investigational #RNAi therapeutic inclisiran, presented by our partner @MDCOnews at #ESCCongress today, offer promise for patients and have important implications for the field of RNAi therapeutics and Alnylam. Our CEO John Maraganore 🇺🇸🇬🇷🇺🇦 shares his thoughts.

Members of our field team, including Mr. Keiji Matsumoto, are now off to work in Japan! Another milestone for Alnylam Pharmaceuticals and #RNAi therapeutics!

Today we announced that we have initiated APOLLO-B, a global Phase 3 clinical trial in transthyretin #amyloidosis (ATTR amyloidosis) with cardiomyopathy. #RNAi

我が母校が第2位にランクイン！

Thrilled to be with ⁦Alnylam Pharmaceuticals⁩ Asia Team and Jeff Poulton discussing how we help patients in the region!!

We are pleased to report that our investigational #RNAi therapeutic previously approved in the US, Canada, the EU and Japan, has been approved by the Brazilian Health Regulatory Agency (ANVISA).

As #RareDiseaseDay comes to a close we reflect back on a truly inspiring week in which our employees across the globe participated in over a dozen different local and Alnylam awareness and patient events and came together as one team to pose for these amazing #ReframeRare photos!

【速報】！！ 日本循環器学会学術集会の延期日程が 【7月30日（木）〜８月2日（日）】 に京都で決定！！ by 情報広報委員K congre.co.jp/jcs2020/

Today, we are delighted to announce that the European Commission (EU Medicines Agency) has approved our #RNAi therapeutic for the treatment of acute hepatic #porphyria, a devastating #raredisease, which until now had limited treatment options.

Earlier, we announced we're expanding our partnership w/ Vir Biotechnology to develop #RNAi therapeutics targeting SARS-CoV-2, the virus that causes #COVID19. Together, we will focus on development of siRNAs recently identified that target highly conserved regions of coronavirus RNAs.

RNAi is a powerful, natural cellular mechanism that can be potentially harnessed for anti-viral therapies. "The ability to deal with [COVID-19] is going to be driven by science and innovation, not by prayer." investors.com/news/technolog…

Alnylam conducted interviews w/ 30 U.S. payer and plan decision-makers about barriers to orphan drug access. Those findings, published in the Alnylam Rare Disease Trend Report, provide critical insight into payers' challenges and opportunities for collaboration to improve access.

Another positive Phase 3 trial for #RNAi in collaboration with Sanofi! #RNAitherapeutics #siRNA